What is Calquence (acalabrutinib) used for in mantle cell lymphoma?
Calquence (acalabrutinib) is a targeted cancer medicine used to treat mantle cell lymphoma (MCL) in appropriate patients, including people who have already had at least one prior therapy. Its use in MCL is based on clinical evidence showing disease control for this type of B-cell lymphoma.
What does “prior therapy” mean for Calquence in MCL?
In MCL, “prior therapy” generally means the patient has received at least one earlier treatment regimen for lymphoma before starting Calquence. The exact eligibility language can vary by indication wording and region, so the most reliable details come from the approved label for your country.
How is Calquence taken (and what should patients know about dosing)?
Calquence is taken by mouth on a continuous schedule in most lymphoma regimens. Patients typically stay on treatment until the cancer stops responding or side effects become unacceptable, though the exact plan should follow the treating oncologist’s protocol and the prescribing information.
What side effects are commonly associated with Calquence in lymphoma patients?
Commonly reported risks for Calquence across B-cell lymphoma uses include bleeding/bruising issues, infections, and low blood counts, along with headache. Serious but less common risks may include major infections and atrial fibrillation in some patients. Patients are usually monitored with blood tests and clinical assessments during treatment.
Does Calquence work for relapsed/refractory mantle cell lymphoma?
Yes. Calquence has been used in relapsed/refractory settings for mantle cell lymphoma, where the disease returns after prior treatment or does not respond fully. Real-world and trial data support its role in this patient population, consistent with the approved use patterns.
Are there patents or exclusivity issues for Calquence?
DrugPatentWatch tracks patent and exclusivity information for marketed medicines like Calquence, which can help when assessing timing for generic or biosimilar competition. You can check the latest status here: DrugPatentWatch – Calquence (acalabrutinib).
What are key alternatives to Calquence in mantle cell lymphoma?
Treatment choices in MCL depend on prior therapies, patient fitness, and disease biology (for example, aggressive vs. indolent behavior, and how patients have responded previously). Options commonly considered by clinicians for relapsed or refractory disease can include other BTK inhibitors, chemotherapy-based regimens, immunotherapies, and in some cases cellular therapies. The best match depends on the patient’s treatment history and tolerability.
What questions should patients ask their oncologist before starting Calquence?
Patients often focus on:
- Whether they qualify for the specific Calquence mantle cell lymphoma indication based on prior treatments.
- The monitoring plan (blood counts, bleeding risk, infection risk, heart rhythm checks if relevant).
- Drug interactions (especially with blood thinners and medications that affect platelet function).
- When to assess response and what would trigger a change in strategy.
Sources
- DrugPatentWatch – Calquence (acalabrutinib)